Rebecca Croasdale

This inventor holds 8 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 6 EPO patents. Top assignees: Hoffmann-La Roche Inc., Roche Glycart Ag. Active years: 2014-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rebecca Croasdale. Retrieved from https://idiyas.com/inventor/rebecca-croasdale

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8 (Patent Applications = 7)

% Patents Active = 87.5

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 11)

Average Co-Inventor Count = 8.3

ph-index = 5

Forward Citations = 141(Granted Patents)

Company Filing History:

6 out of 5,027

Hoffmann-La Roche Inc.

Years Active: 2014-2024

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11993642 - Trivalent, bispecific antibodies (2024-05-28),

2. 10106600 - Bispecific antibodies (2018-10-23),

3. 9890204 - Trivalent, bispecific antibodies (2018-02-13),

4. 9574016 - Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent (2017-02-21),

5. 9382323 - Multispecific antibodies comprising full length antibodies and single chain fab fragments (2016-07-05),

6. 9050375 - Bi-specific digoxigenin binding antibodies (2015-06-09),

7. 8907069 - Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent (2014-12-09),

8. 8796424 - Tri- or tetraspecific antibodies (2014-08-05),

Title: Celebrating the Innovations of Inventor Rebecca Croasdale

Introduction

Rebecca Croasdale, an accomplished inventor based in Antdorf, Germany, has made significant contributions to the field of biotechnology. With a remarkable portfolio of eight patents, her work primarily revolves around the development of innovative antibody technologies. Her inventions have considerable implications in the pharmaceutical industry, paving the way for advanced therapeutic options.

Latest Patents

Among her latest patents are two notable innovations:

1. **Trivalent, Bispecific Antibodies** - This invention involves the production of trivalent, bispecific antibodies, along with pharmaceutical compositions containing these antibodies and their various uses.

2. **Bispecific Antibodies** - This patent details methods for producing bispecific antibodies, the pharmaceutical compositions that incorporate these antibodies, and their applications in medical treatment.

Career Highlights

Rebecca has worked with prominent companies in the biotech sector. Notably, she has been associated with Hoffmann-La Roche Inc. and Roche Glycart AG, where she has leveraged her expertise to advance research and development in antibody therapies. Her innovative approach has garnered recognition and solidified her reputation as a leading inventor in her field.

Collaborations

Throughout her career, Rebecca has collaborated with esteemed professionals, including her coworkers Ulrich Brinkmann and Christian Klein. These partnerships have been instrumental in driving her projects forward, enhancing the quality and impact of her inventions.

Conclusion

Rebecca Croasdale's contributions to biotechnology highlight her role as a pivotal inventor in the development of antibody therapies. Her continuous efforts in research and innovation underscore the importance of her work in improving therapeutic outcomes for patients worldwide. With her impressive patent portfolio and collaborations, Rebecca remains a notable figure in the realm of scientific advancement.

Profile summary based on public USPTO records.